With over 35 nationalities and a range of backgrounds represented in our Benevolent team, we aim to build an inclusive environment where our people can bring their authentic selves to work, be respected for who they are and the exceptional work they do. We welcome and actively encourage applications from all sections of society and are committed to offering equal employment opportunities regardless of sex, race, religion or belief, ethnic or national origin, marital, domestic or civil partnership status, sexual orientation, gender identity, parental status, disability, age, citizenship, or any other basis. We see our diversity as an asset as we tackle challenging problems that bridge the gap between drug discovery and technology.
As Product Manager for Knowledge, you will work with the Product Area Lead contributing towards defining the BenevolentAI data pipeline, ETL, and data access strategy, identifying our informatician and engineer user needs and setting the product objectives of your team and collaborate with our ML Engineering team to develop state of the art NLP algorithms for extracting biological data from text.
We are keen to hear from technical Product Managers with experience working with data engineering and AI/ML-focussed teams with experience in multimodal data including; structured, experimental, and NLP-derived and with a proven track record building technical products that create significant impact for their users.
Challenging and meaningful, this role will give you a chance to bring your own experience, ideas, and creativity to push forward exciting projects quickly with the chance to try genuinely new ways to find medicines.
We share a passion for being part of a mission that matters, and we are always looking for curious and collaborative people who share our values and want to be part of our journey. If that sounds like a fit for you, hit the apply button and join us.
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Our team will only contact you from the domain @benevolent.ai. If you receive a suspicious contact request, please email email@example.com. Thank you.